Health News Releases

July 12, 2017 17:30

Octapharma Symposium At ISTH Berlin Supports Progress in Lifelong Treatment of High-Risk Patients With Von Willebrand Disease (VWD) and haemophilia A

Octapharma is pleased to announce the success of yesterday’s symposium at the International Society on Thrombosis and Haemostasis (ISTH) congress held in Berlin, Germany. As platinum sponsors of the c

July 11, 2017 18:40

Final Phase III Study Results Confirm Benefit of Praxbind® as Reversal Agent for Pradaxa® Patients in Emergency Situations

Boehringer Ingelheim today announced final results from RE-VERSE AD™.[1,2] The study shows that Praxbind® (idarucizumab) was able to immediately and completely reverse the anticoagulant effect of Prad

July 11, 2017 13:50

ISTH 2017, Berlin: Octapharma presents exciting Nuwiq® data in previously untreated patients and demonstrates real-life value of personalised prophylaxis for Haemophilia A

Octapharma is playing a prominent role this week at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Berlin, Germany. As a platinum sponsor of the congress, Octapharma’s acti

July 11, 2017 13:20

Masimo Announces CE Marking of rainbow® Super Sensor

Masimo (NASDAQ: MASI) announced today the CE marking of the rainbow® Super DCI®-mini sensor, a reusable spot-check sensor that features Masimo SET® Measure-through Motion and Low Perfusion™ pulse oxim

July 07, 2017 14:40

Octapharma Activities Prominent at the Upcoming 2017 ISTH Congress in Berlin, Germany

Octapharma today announced that it will be actively involved in a wide range of activities at this year’s International Society on Thrombosis and Haemostasis (ISTH) Congress. The Congress will be held

July 07, 2017 11:00

Solmedix and Mobiuso sign MOU to develop the MOSAIC Platform Software for innovative medical device

Solmedix Co., Ltd announced that Solmedix (CEO Yang In-chul, Seoul, Korea) and Mobiuso LLC (President Santhosh Kumaraswamy, New York, United State) signed an MOU for joint development of software and

July 06, 2017 10:55

Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers

Celgene Corporation (NASDAQ:CELG) and BeiGene, Ltd. (NASDAQ:BGNE) entered into a strategic collaboration to develop and commercialize BeiGene’s investigational anti-programmed cell death protein 1 (PD

July 03, 2017 16:40

Ferring Appoints Lars Peter Brunse to Executive Board

Ferring Pharmaceuticals announced today that Lars Peter Brunse has been appointed Executive Vice President and Chief Production Officer, and made a member of the Ferring Executive Board, effective imm

June 29, 2017 20:10

‘More than Systemic Sclerosis: The Inside Story’ - patients reveal the unseen impact of lung fibrosis

‘More than Systemic Sclerosis: The Inside Story’ launches today to mark World Scleroderma Day. This global initiative highlights the importance of understanding the ‘inside story’ of each individual l

June 28, 2017 13:30

Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that the Phase 3 ECHELON-1 clinical trial met its primary endpoint of a statistically signifi

June 26, 2017 09:55

Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that data from two Phase 1/2 clinical trials evaluating NINLARO™ (ixazomib) in patients with newly diagnosed multiple myeloma will be

June 22, 2017 17:15

Bionext Launches Biosight: an Online Platform That Will Revolutionize Pharmaceutical Research

Bionext, a bioinformatics company, announces today the launch of BioSight, an online bio-simulation platform designed for efficient identification of possible side effects of potential drug treatments

June 21, 2017 18:05

New data reveal high rates of stroke history in asymptomatic atrial fibrillation patients

Boehringer Ingelheim today announced findings from GLORIA™-AF which show that people with non-valvular atrial fibrillation (AF) with few or no symptoms are more likely to have had a stroke prior to AF

June 20, 2017 17:30

New Study Compares Performance of Masimo Next Generation SedLine® Patient State Index (PSi) to Original PSi During Anesthesia

Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at Euroanaesthesia 2017 in Geneva, Switzerland. In the study, researchers at University Medical Center Groningen, Netherland

June 19, 2017 22:00

First-Ever World Kidney Cancer Q&A Day Highlights Growing Global Burden

Kidney cancer is a silent disease that’s on the rise. The global incidence of kidney cancer is predicted to increase by a shocking 22 percent by 2020. Explanations are incomplete, but include risk fac

June 19, 2017 16:45

Herbalife Nutrition Encourages North Asia Members to Play a Bigger Role in Inspiring Healthy Active Living in Their Local Communities

Global nutrition company, Herbalife (NYSE:HLF), has concluded its annual Asia Pacific Extravaganza for North Asia, held from June 16 to 18 in Hong Kong. As a training event organized for Herbalife Nut

June 16, 2017 13:55

Merck Becomes Member of the Worldwide Innovative Network in Personalized Cancer Medicine - WIN Consortium (Paris)

Worldwide Innovative Network in Personalized Cancer Medicine - WIN Consortium proudly announces today that Merck, which operates its biopharmaceutical business as EMD Serono in the U.S. and Canada, be

June 15, 2017 12:10

SERMO Announces Massive Global Expansion, Now Available in More Than 150 Countries

SERMO - the largest global social network for physicians that is revolutionizing medical crowdsourcing - today furthered its goal of uniting doctors worldwide by expanding to more than 150 countries.

June 15, 2017 11:35

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®

Boehringer Ingelheim announced today results from the pivotal Phase III VOLTAIRE®-RA[1] study, confirming that its adalimumab biosimilar candidate BI 695501 and HUMIRA®* have similar efficacy, safety

June 15, 2017 11:25

Phase 2a Safety and Efficacy Data Support Further Development of Oral CC-220 in Patients with Lupus

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results from the phase 2a SLE-001 trial evaluating CC-220, the Company's investigational, or

June 15, 2017 11:15

Pimodivir Alone or in Combination with Oseltamivir Demonstrated a Significant Reduction in Viral Load in Adults with Influenza A

Janssen Pharmaceuticals, Inc. (Janssen) today announced results from the Phase 2b Topaz Trial which demonstrated that treatment with pimodivir (JNJ-63623872) significantly decreased viral load over se

June 13, 2017 11:55

Kieran Murphy Appointed CEO of GE Healthcare, Succeeding John Flannery

GE Chairman and CEO Jeff Immelt announced today the appointment of Kieran Murphy as president and CEO of GE Healthcare, effective immediately. Murphy is currently president and CEO of GE Healthcare Li

June 13, 2017 11:15

New Study Investigates the Clinical Utility of ORi™, Masimo Oxygen Reserve Index™

Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at the recent International Anesthesia Research Society (IARS) Annual Meeting in Washington, DC. In the study, researchers a

June 08, 2017 18:55

Takeda and Seattle Genetics Announce Lancet Publication of Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the randomized Phase 3 ALCANZA clinical trial evaluating ADCETRIS (brentuximab

June 08, 2017 16:45

Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation

Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced new efficacy and safety data from the ongoing Phase 1 dose-escalation and expansion study evaluating inv

News by Region

News by Industry